Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non-Current Assets (2022 - 2024)

NewAmsterdam Pharma (NAMS) has disclosed Other Non-Current Assets for 3 consecutive years, with $8000.0 as the latest value for Q2 2024.

  • Quarterly Other Non-Current Assets changed N/A to $8000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $8000.0 through Jun 2024, changed N/A year-over-year, with the annual reading at $35000.0 for FY2023, 77.56% down from the prior year.
  • Other Non-Current Assets hit $8000.0 in Q2 2024 for NewAmsterdam Pharma, down from $16000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $156000.0 in Q4 2022 to a low of $8000.0 in Q2 2024.
  • Historically, Other Non-Current Assets has averaged $53750.0 across 3 years, with a median of $25500.0 in 2023.
  • Biggest YoY gain for Other Non-Current Assets was 77.56% in 2023; the steepest drop was 77.56% in 2023.
  • Year by year, Other Non-Current Assets stood at $156000.0 in 2022, then crashed by 77.56% to $35000.0 in 2023, then crashed by 77.14% to $8000.0 in 2024.
  • Business Quant data shows Other Non-Current Assets for NAMS at $8000.0 in Q2 2024, $16000.0 in Q1 2024, and $35000.0 in Q4 2023.